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Background: Roxadustat (FG-4592) is anoral hypoxia-inducible factor prolyl-hydroxylase inhibitor that promotes
erythropoiesis through increasing endogenous erythropoietin, improving iron regulation, and reducing hepcidin.
Study Design: Phase 2, randomized (3:1), open-label, active-comparator, safety and efficacy study.
Setting & Participants: Patients with stable end-stage renal disease treated with hemodialysis who
previously had hemoglobin (Hb) levels maintained with epoetin alfa.
Intervention: Part 1: 6-week dose-ranging study in 54 individuals of thrice-weekly oral roxadustat doses
versus continuation of intravenous epoetin alfa. Part 2: 19-week treatment in 90 individuals in 6 cohorts
with various starting doses and adjustment rules (1.0-2.0 mg/kg or tiered weight based) in individuals with a
range of epoetin alfa responsiveness. Intravenous iron was prohibited.
Outcomes: Primary end point was Hb level response, defined as end-of-treatment Hb level change (DHb)
of 20.5 g/dL or greater from baseline (part 1) and as mean Hb level $ 11.0 g/dL during the last 4 treatment
weeks (part 2).
Measurements: Hepcidin, iron parameters, cholesterol, and plasma erythropoietin (the latter in a subset).
Results: Baseline epoetin alfa doses were 138.36 51.3 (SD) and 136.36 47.7 U/kg/wk in part 1 and
152.86 80.6 and 173.46 83.7 U/kg/wk in part 2, in individuals randomly assigned to roxadustat and epoetin alfa,
respectively. Hb level responder rates in part 1 were 79% in pooled roxadustat 1.5 to 2.0 mg/kg compared to 33%
in the epoetin alfa control arm (P5 0.03). Hepcidin level reduction was greater at roxadustat 2.0 mg/kg versus
epoetin alfa (P, 0.05). In part 2, the average roxadustat dose requirement for Hb level maintenance was
w1.7 mg/kg. The least-squares-mean DHb in roxadustat-treated individuals was comparable to that in epoetin
alfa–treated individuals (about 20.5 g/dL) and the least-squares-mean difference in DHb between both
treatment arms was 20.03 (95% CI, 20.39 to 0.33) g/dL (mixed effect model-repeated measure). Roxadustat
significantly reducedmean total cholesterol levels, not observedwith epoetin alfa. No safety concernswere raised.
Limitations: Short treatment duration and small sample size.
Conclusions: In this phase 2 study of anemia therapy in patients with end-stage renal disease on
maintenance hemodialysis therapy, roxadustat was well tolerated and effectively maintained Hb levels.
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Roxadustat in Dialysis-Dependent CKD Anemia(NHCT), the Correction ofHemoglobin andOutcomes in
Renal Insufﬁciency (CHOIR) study, the Cardiovascular
RiskReductionbyEarlyAnemiaTreatmentWithEpoetin
Beta (CREATE) study, and the Trial to Reduce Cardio-
vascular Events With Aranesp Therapy (TREAT),2-5
which targeted hemoglobin (Hb) values . 11 g/dL,
prompted regulatory authorities to institute warnings to
use the lowest ESA dose adequate for reducing the need
for red blood cell transfusion. Thewarning also states that
no trial has identiﬁed an Hb target level, ESA dose, or
dosing strategy that does not increase these risks.6 Similar
recommendations have also been made based on obser-
vational studies.7Post hocanalysesof thementioned trials
point to highESAdoses as themediator of cardiovascular
risk while consistently supporting an inverse relationship
between achieved Hb levels and risk.8 These restrictions
on ESAs have subsequently been associated with a
decline in Hb levels and an increase in transfusions in
patients with ESRD in the United States.9
Hepcidin has been recently identiﬁed as the master
regulator of iron metabolism,10,11 and levels are
elevated in patients with ESRD12 and those with
inﬂammation. Hepcidin reduces duodenal iron ab-
sorption and export of tissue-stored iron-impairing
responsiveness to erythropoietin (EPO). Anemia in
patients with ESRD is not simply an “EPO-deﬁciency
state,” but one of EPO dysregulation coupled with
major abnormalities in iron metabolism leading to the
need for intravenous (IV) iron.13 Recent studies
demonstrate a role for hypoxia-inducible factor (HIF)
in the regulation of endogenous EPO production, the
iron transport system,14 and hepcidin. A new class of
drugs, HIF2prolyl hydroxylase inhibitors (HIF-
PHIs), taking advantage of natural physiology in co-
ordinated erythropoiesis, is being evaluated for the
treatment of anemia in chronic kidney disease.15
Roxadustat (FG-4592) is an orally bioavailable
HIF-PHI with a half-life of around 12 hours; thrice-
weekly administration leads to intermittent activation
of genes associated with erythropoiesis, notably
including well-characterized HIF targets such as EPO
and proteins promoting iron absorption, iron trans-
port, and heme synthesis.16-18 In an earlier placebo-
controlled 4-week phase 2a study, roxadustat
increased Hb levels in non–dialysis-dependent pa-
tients with chronic kidney disease in a dose-
dependent manner and improved iron homeostasis,
limiting transient endogenous EPO levels to within or
near physiologic range.19 In ESA-naive incident he-
modialysis and peritoneal dialysis patients, roxadustat
treatment resulted in a maximum Hb level increase
of 13.1 6 0.2 (standard error [SE] of the mean) g/dL
over 12 weeks despite a lack of iron repletion
requirement at baseline, with Hb values of hemodi-
alysis patients receiving oral iron responding as well
as those on IV iron therapy.20 We present a phase 2Am J Kidney Dis. 2016;67(6):912-924study of patients with ESRD on maintenance hemo-
dialysis therapy whose Hb levels had been previously
maintained by epoetin alfa, randomly assigned to
roxadustat or to continue epoetin alfa to demonstrate
roxadustat’s efﬁcacy in maintaining Hb levels when
converting from an ESA and to establish the optimum
starting dose and dose adjustment regimen to main-
tain target Hb values.
METHODS
Study Design
This was a randomized, multicenter, open-label, consecutive-
cohort, multidose study with active comparator IV epoetin alfa
in patients with ESRD treated by maintenance hemodialysis in
the United States whose Hb levels were previously maintained
with IV epoetin alfa (dosage, 75-450 U/kg/wk) and IV iron in
the 4 weeks preceding screening. The study, conducted be-
tween May 17, 2010, and October 15, 2012, consisted of a
screening period of up to 4 weeks, a treatment period of 6 (part
1) or 19 (part 2) weeks, and an 8- (part 1) or 4-week (part 2)
follow-up period.
The study was approved by Aspire Institutional Review Board,
La Mesa, CA. Participants provided written informed consent.
Participants and Treatment
Eligible patients were aged 18 to 75 years and receiving
maintenance hemodialysis thrice weekly for 4 or more months. Hb
levels were 9.0 to 13.5 g/dL for 8 weeks, and patients had stable
epoetin alfa dosages # 450 U/kg/wk for 4 weeks prior to
randomization. A comprehensive list of eligibility criteria is pro-
vided (Item S1).
The study design is illustrated in Fig 1. Part 1 consisted of 3.5
consecutive 6-week dose cohorts in which participants were
randomly assigned up to n 5 16 per cohort, 3:1 (roxadustat to
epoetin alfa), with oral roxadustat doses ﬁxed at 1.0, 1.5, 1.8, or
2.0 mg/kg thrice weekly. Results of part 1 were used to reﬁne
optimal roxadustat starting doses for part 2 (19-week treatment),
consisting of 6 consecutive-dose cohorts in which participants
were converted to roxadustat from epoetin alfa treatment (Table 1).
Part 2 comprised 90 patients randomly assigned to 6.5 cohorts of
roxadustat (n 5 67, with various starting doses) or to continue on
epoetin alfa therapy (n 5 23).
Treatment with androgens was prohibited; IV iron use and red
blood cell transfusions were guided by rescue criteria (Item S2).
Oral iron supplementation was permitted but not required. During
the post-treatment follow-up period, roxadustat-treated patients
switched back to epoetin alfa.
Dose Modiﬁcations
Hb was measured weekly; investigators titrated the roxadustat
dose after the initial ﬁxed dosing period based on cohort-speciﬁc
rules every 4 weeks (Table 2). If Hb level increased by .2.0 g/
dL in any 2 weeks, the dose was reduced 1 dose step. For par-
ticipants randomly assigned to epoetin alfa, dose adjustments were
made based on the local standard of care.
Assessments
The primary end point in part 1 (6-week cohorts) was the pro-
portion of participants whose Hb levels did not decrease by
.0.5 g/dL from baseline (deﬁned as the mean of the last 3 Hb
values obtained prior to the ﬁrst dose of study treatment). The
primary end point in part 2 (19-week cohorts) was the proportion
of participants whose mean Hb level was $11 g/dL averaged over
the last 4 weeks (weeks 16 through 19). Exploratory analysis913
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Figure 1. Study scheme. Abbreviations: IV, intravenous; pt, patient; TIW, thrice weekly.
Provenzano et alincluded hepcidin levels, correlates of erythropoiesis and iron use
(reticulocyte Hb content, soluble transferrin receptor, transferrin,
total iron-binding capacity, transferrin saturation, and ferritin), and
total serum cholesterol level.
Safety was assessed by physical examinations, clinical labora-
tory tests, and the incidence and severity of adverse events (AEs)
recorded from treatment onset through follow-up.
Evaluation of plasma endogenous EPO levels was conducted at
selected sites to compare circulating endogenous EPO levels 0 to 48
hours following roxadustat treatment with EPO levels followingTable 1. Roxadusta
Treatment
Cohort
Treatment
Duration, wk
Criterion for Epoetin
alfa Dose Preceding Study Drug
Treatment, IU/kg/dose
We
Do
A-1 6 25-85 1.
A-2 6 25-85 1.
A-3 6 25-85 2.
A-4 6 25-85 1.
A-5 19 85-115 1.
A-6 19 25-115 1.
A-7 19 25-115 W
A-8 19 25-115 W
A-9 19 85-150 2.
A-10 19 25-115 W
Note: Weight indicates posthemodialysis actual dry weight at base
aAll regimens 3 times per week.
bAmendment 2 increased the number of cohorts from 4 to 10, exte
participants in cohort A-4 and all participants in the new cohorts, an
cAmendment 3 allowed dose adjustments to be made after 4 week
modified some dose adjustment rules. It also added cohorts A-11 an
dDoses given are for participant weights of 45 to 60, .60 to 90, a
914exogenous administration of epoetin alfa dosed within the same
participants prior to randomization.
Statistical Analysis
The study was not formally powered for noninferiority; the total
number of patients and cohort size were considered adequate for
phase 2 studies to advise medical decision making and assess
relative efﬁcacy. All analyses were exploratory. All participants
receiving any dose of study treatment were included in the safety
population and safety analyses.t Starting Doses
ight-Based Starting
se of Roxadustata
Fixed Period for
Initial Dosing, wk
0 mg/kg 3
5 mg/kg 3
0 mg/kg 3
8 mg/kg 3
8 mg/kg 6 (amendment 2b) then
4 (start amendment 3c)
3 mg/kg 6
eight tiered: 70-100-150 mgd 6 then 4 (start amendment 3c)
eight tiered: 70-120-200 mgd 4
0 mg/kg 4
eight tiered: 70-120-200 mgd 4
line.
nded treatment duration from 6 to 19 weeks for the 5 remaining
d reduced the follow-up period from 8 to 4 weeks.
s rather than 6 weeks, allowed more rapid dose escalation, and
d A-12, which were not filled eventually.
nd .90 to 140 kg, respectively.
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Table 2. Dose Adjustments That Took Effect under Amendment 3
DHb Over
Past 4 wk, g/dL
Hb , 11.0
g/dL
Hb 11.0-,13.0
g/dL
Hb 13.0-14.0
g/dL Hb . 14.0 g/dL
,20.8 [ [ No change Hold, then resume dosing when
Hb, 12.0 g/dL at a dose that is reduced
by 2 dose steps
20.8 to 0.8 [ No change Y
.0.8 No change Y Y
Note: Dose increases ([) and reductions (Y) are to be in dose steps as follows: 0, 20, 40, 50, 70, 100, 120, 150, 200, 250, 300, 350,
and 400 mg. Generally, dose was reduced 1 step at a time, but may have been reduced by 2 dose steps as needed. The maximum
dose was set at 3.0 mg/kg, but could be increased to 3.5 mg/kg with approval from sponsor. If Hb level has increased by .1.5 g/dL
from the baseline Hb value during the first 21 days of dosing, dose was reduced by 1 step (eg, reduction from 100 to 70 mg). If Hb level
increased by .2.0 g/dL during any 2-week period, dose was reduced by 1 dose step.
Abbreviations: DHb, change in hemoglobin; Hb, hemoglobin.
Roxadustat in Dialysis-Dependent CKD AnemiaThe efﬁcacy-evaluable population in both part 1 (6-week study)
and part 2 (19-week study) included eligible participants who
received treatment for 4 or more weeks with corresponding Hb
measurements that had not resulted from any rescue therapies (IV
iron or red blood cell transfusion) or inadvertent use of ESAs. The
efﬁcacy-evaluable population also included all participants who
permanently discontinued study medication during the dosing
period due to lack of efﬁcacy. A post hoc intention-to-treat anal-
ysis was also performed on the primary end point for participants
in parts 1 and 2.
The safety and efﬁcacy analyses presented here were based on
pooled roxadustat-treated participants across the various dose co-
horts and compared with pooled IV epoetin-alfa participants.
Mixed model of repeated measurements and/or analysis of
covariance/nonparametric models were used for continuous end
points, and c2 or Fisher exact tests, for categorical end points. All
alternative hypotheses and statistical comparisons were 2 sided
(a 5 0.05). No adjustments for multiplicity were made due to the
exploratory nature of the analysis. All null hypotheses were no
treatment difference unless speciﬁed otherwise. Results are pre-
sented as mean 6 standard deviation (SD) or mean 6 standard
error of the mean.
The effect of inﬂammation on dose needs was examined by
correlating (linear regression) maintenance dose requirements of
epoetin alfa or roxadustat to C-reactive protein (CRP) level, a
surrogate for inﬂammatory state, at baseline (average of last 3
pre2ﬁrst-dose values) or last 7 of 19 weeks’ averages (mainte-
nance phase), respectively, in all efﬁcacy-evaluable participants
randomly assigned to 19 weeks of roxadustat treatment and dosed
beyond 12 weeks, with valid pre-enrollment epoetin alfa dose data
and valid baseline and maintenance phase CRP data (n 5 49).
All safety data were tabulated using descriptive statistics.
RESULTS
Participant Disposition and Characteristics
A total of 144 participants with baseline stable
epoetin alfa doses were randomly assigned (3:1) to
roxadustat or epoetin alfa; all were dosed and consti-
tuted the safety population. Part 1 comprised 54 par-
ticipants treated for 6 weeks (41 roxadustat and 13
epoetin alfa); part 2 comprised 90 participants treated
for 19 weeks (67 roxadustat and 23 epoetin alfa).
Reasons for discontinuation from the study were lack
of efﬁcacy (n 5 10), withdrawal of consent (n 5 4),
AE/serious AE (SAE; n 5 6; including 3 deaths), 3
protocol violations, and 3 others (leaving center, pro-
longed hospitalization, and kidney transplantation).Am J Kidney Dis. 2016;67(6):912-924There were 125 participants who were efﬁcacy-
evaluable (ﬂow diagram available as Fig S1). In gen-
eral, demographics and baseline characteristics for the
randomization arms were statistically similar
(Table 3). Mean baseline Hb levels for treatment arms
ranged from 11.2 to 11.5 g/dL.
Efﬁcacy During 6 Weeks of Treatment
In part 1, a total of 41 participants were randomly
assigned to 1 of 4 roxadustat dose cohorts (1.0, 1.5,
1.8 [this cohort was only partly ﬁlled], and 2.0 mg/kg
thrice weekly), and 13 participants, to the epoetin alfa
control arm. The primary end point was Hb level
of 20.5 g/dL or greater from baseline by the end of 6
weeks. Roxadustat had a dose-response effect on Hb
levels (Fig 2A). The cohort with the lowest roxadustat
dose (1.0 mg/kg) was comparable to epoetin alfa with
an Hb level responder rate of 44% as compared to
33%, respectively. Roxadustat doses $ 1.5 mg/kg
maintained a higher responder rate than epoetin alfa,
with a pooled responder rate of 79% (P 5 0.03;
Fig 2A). Intention-to-treat analysis showed similar
results: 63% of all roxadustat participants versus 31%
of epoetin alfa participants (P 5 0.06).
Overall, mean change from baseline in Hb level
(DHb) after 6 weeks was an increase of 0.3 g/dL in
roxadustat-treated participants versus a decrease of
1.0 g/dL in the epoetin alfa group. Mean DHb values
were signiﬁcantly greater for 1.5 mg/kg thrice weekly
(10.9 g/dL; P 5 0.03) and 2.0 mg/kg of roxadustat
thrice weekly (10.7 g/dL; P 5 0.04) than in the
epoetin alfa group. Five of 41 (12%) roxadustat-treated
and 2 of 13 (15%) epoetin alfa–treated participants
received IV iron for rescue during the treatment phase.
Efﬁcacy During 19 Weeks of Treatment
In part 2, a total of 67 participants were randomly
assigned to the remainder of Cohort A-4 (1.8 mg/kg)
and 6 additional roxadustat cohorts (Table 1), and 23
participants were randomly assigned to continue
epoetin alfa treatment. For roxadustat overall, 31 of
61 (51%) efﬁcacy-evaluable participants achieved915
Table 3. Subject Demographics and Baseline Characteristics: Safety Population and 6- and 19-Week Treatment Durations
Characteristic
6-wk Treatment Duration 19-wk Treatment Duration
Roxadustat (n 5 41) Epoetin alfa (n 5 13) Roxadustat (n 5 67) Epoetin alfa (n 5 23)
Age, y 55.8 6 13.4 59.5 6 10.1 56.96 12.1 57.0 6 11.6
Age range, y 20-79 39-75 20-80 29-78
Male sex 27 (66%) 9 (69%) 45 (67%) 14 (61%)
Weight, kg 83.4 6 19.0 78.7 6 18.1 86.66 22.5 84.3 6 23.4
Race
White 27 (66%) 5 (39%) 35 (52%) 6 (26%)
Black 13 (32%) 7 (54%) 29 (43%) 12 (52%)
Asian 1 (2%) 1 (8%) 1 (2%) 3 (13%)
Other 0 (0%) 0 (0%) 2 (3%) 2 (9%)
Prevalencea of
Hypertension 40 (98%) 13 (100%) 66 (100%); n 5 66b 22 (100%); n 5 22b
Diabetes 28 (68%) 10 (77%) 39 (59%); n5 66b 14 (64%); n5 22b
Baseline epoetin alfa dose, IU/kg/wk 138.3 6 51.3; n5 37 136.36 47.7; n 5 13 152.86 80.6; n 5 66 173.46 83.7; n5 22
Hb, g/dL 11.36 0.6 11.56 0.6 11.2 6 0.7 11.2 6 1.0
Ferritin, mg/mL 912.56 419.3 875.6 6 449.8 827.76 474.3 1,065.86 657.2
TSAT, % 30.46 8.0 30.4 6 10.2 29.26 10.0 28.1 6 14.4
Abbreviations: Hb, hemoglobin; TSAT, transferrin saturation.
aBased on the occurrence of diabetes and hypertension reported on the Medical History Case Report Form.
bPresented as N and % of total with available data followed by presentation of the total number of patients for whom data was
available.
Provenzano et alaverage Hb levels $ 11.0 g/dL over the last 4 weeks of
the 19-week treatment period (primary end point)
compared with 8 of 22 (36%) epoetin alfa–treated
participants. Analysis of the intention-to-treat set was
similar: 33 of 67 (49%) roxadustat-treated participants
compared with 8 of 23 (35%) epoetin alfa–treated
participants. Roxadustat-treated participants (indivi-
dual dose cohorts and overall) treated for 19 weeks did
not signiﬁcantly differ from epoetin alfa–treated8
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Figure 2. Hemoglobin levels over time (6 weeks) by treatment
randomly assigned to 6 weeks of treatment in part 1. Hb level resp
Hb levels did not decrease by .0.5 g/dL from their baseline (primary
over time (19 weeks), roxadustat-treated versus epoetin alfa–treated
are epoetin alfa (n5 22). *P values are from Fisher exact test (2 side
dard error (SE) of the mean.
916participants in DHb at any time point out to 19 weeks
(mixed model-repeated measures; Fig 2B). For the
pooled roxadustat dose cohorts, the least-squares-
mean DHb was 20.56 0.2 (SE) g/dL compared
to 20.5 6 0.3 g/dL in the epoetin alfa arm, and the
least-squares-mean difference from the epoetin alfa
arm in DHb was20.03 g/dL (95% conﬁdence interval
for the difference from epoetin alfa in DHb, 20.39 to
0.33 g/dL). The mean roxadustat dose requirement for4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19
Treatment Duration (Weeks)
group. (A) Hb levels over time by dose cohort for participants
onders are defined as the number (percent) of patients whose
efficacy end point in part 1). (B) Least squares mean Hb levels
patients. Closed diamonds are roxadustat (n 5 61); open circles
d) comparing roxadustat with epoetin alfa. Error bars signify stan-
Am J Kidney Dis. 2016;67(6):912-924
Roxadustat in Dialysis-Dependent CKD AnemiaHb level maintenance was 1.68 6 0.65 (SD; range,
0.58-3.39) mg/kg thrice weekly, with starting doses
being weight based or tiered weight based (Table S1).
There were no signiﬁcant differences in weekly doses
over time among dose cohorts except for one cohort in
which baseline epoetin alfa doses were 2-fold higher
than the other cohorts. Two of 67 (3%) roxadustat-
treated and 3 of 23 (13%) epoetin alfa–treated partic-
ipants received IV iron for rescue (P 5 0.1).
Efﬁcacy in Participants With Versus Without
Inﬂammation
We compared roxadustat versus epoetin alfa
maintenance dose requirements in all participants
randomly assigned to 19 weeks of roxadustat treat-
ment and dosed beyond 12 weeks (maintenance
phase) with valid pre-enrollment epoetin alfa dose
data and valid baseline and maintenance phase CRP
data (see Methods). As documented by others,21
inﬂammation as reﬂected by baseline serum CRP
levels was associated with increased pre-enrollment
epoetin alfa maintenance dose requirements in these
participants (Fig 3A; P 5 0.02). However, in the
same participants with Hb levels maintained with
roxadustat beyond 12 weeks, average weekly rox-
adustat maintenance dose requirements during the last
7 weeks of therapy were not associated with CRP
levels obtained concurrently (Fig 3B; P 5 0.7).
Exploratory Measures
In a subgroup of 6 participants, EPO was measured
prerandomization following IV epoetin alfa injectionA B
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Am J Kidney Dis. 2016;67(6):912-924and then compared with endogenous EPO levels
during treatment with roxadustat (Fig 4A). Mean peak
EPO levels in participants receiving epoetin alfa
(median dose, 90 U/kg/wk) were w700 mIU/mL
compared to a peak of levels ofw130 mIU/mL at 12
hours in participants receiving a mean roxadustat dose
of 1.3 mg/kg.
A progressive decrease in hepcidin levels was
observed in participants treated at higher doses of
roxadustat for 6 weeks (part 1: Fig 4B; Table 4),
compared to epoetin alfa. Reduction of hepcidin
levels was noted at the end of the 19-week treatment;
overall mean change from baseline in roxadustat-
treated participants was 260.4 6 187.8 (SD) ng/mL
(n 5 46) versus 135.6 6 123.4 ng/mL (n 5 18) in
the epoetin alfa–treated pool (P 5 0.04). Reticulocyte
Hb content was maintained at statistically higher than
baseline levels through most of the roxadustat treat-
ment duration, whereas this phenomenon was tran-
sient for 3 weeks only with epoetin alfa (Fig 4C).
Transferrin saturation and serum iron levels were not
different in the treatment groups.
Total cholesterol levels (nonfasting) were reduced
during roxadustat treatment but were without signiﬁ-
cant change in participants continuing epoetin alfa
treatment (Fig 4D).
Safety
AE and SAE rates were consistent with back-
ground disease of this ESRD population. In the
safety population, 69 of 108 (63.9%) roxadustat-
treated and 22 of 36 (61%) epoetin alfa–treated0
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m roxadustat treatment for lack of efficacy (see Fig S1). Baseline
of study drug. CRP is plotted on the x-axis using a logarithmic
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Figure 4. Pharmacodynamic effects of roxadustat compared to epoetin alfa. Error bars signify standard error of the mean. (A)
Mean plasma erythropoietin levels during treatment with roxadustat compared to prior epoetin alfa dosing in the same patients
(n5 6). (B) Change in hepcidin level (ng/mL) from baseline during 6 weeks of treatment in the 6-week cohorts with the largest sample
sizes (n. 5). *P , 0.05 (comparing hepcidin change from baseline between the 2.0-mg/kg roxadustat group and the epoetin alfa
group). (C) Mean reticulocyte hemoglobin content (CHr) over time in roxadustat- versus epoetin alfa–treated participants randomly
assigned to 19 weeks of treatment (last observation carried forward [LOCF], efficacy-evaluable population). (D) Total cholesterol levels
over time in roxadustat- versus epoetin alfa–treated participants randomly assigned to 19 weeks of treatment (LOCF, safety
population).
Provenzano et alparticipants had at least 1 AE. Thirty-two of 144
(22.2%) participants in the safety population had a
total of 50 treatment-emergent SAEs (Table 5). Of
roxadustat-treated participants, 26 of 108 (24.1%)
had at least 1 SAE. The only SAE considered as
possibly related to roxadustat treatment was acute
pancreatitis, diagnosed 2 days after the patient
completed 43 days of treatment. Both the sponsor
and the independent data monitoring committee
considered it unrelated because of a potential alter-
native cause (detailed under Table 5) and the patient
had a recurrent episode 28 months after the last dose
of study medication. Of epoetin alfa–treated partici-
pants, 6 of 36 (17%) had at least 1 SAE.
Exploratory safety analysis of a composite safety
event consisting of death, myocardial infarction,918stroke, heart failure requiring hospitalization, unstable
angina requiring hospitalization, or thromboembolism
in the 19-week participants deﬁned post hoc showed
a numerically lower rate in roxadustat-treated as
compared with epoetin alfa–treated participants.
Among participants in the roxadustat group, 8 of 66
(12%) as compared to 4 of 23 (17%) receiving
epoetin alfa had a composite safety event. Three
roxadustat-treated participants died during the
study: a 68-year-old man with known heart failure
and coronary and peripheral arterial disease had
an unwitnessed death, a 77-year-old man with
methicillin-resistant Staphylococcus aureus sepsis,
and a 58-year-old man with preexisting allergy to
dialysis and cardiovascular disease (acute myocardial
infarction, stent, and transient ischemic attacks) priorAm J Kidney Dis. 2016;67(6):912-924
Table 4. Change From Baseline in Iron Use Parameters, Last Observation Carried Forward
6 wk 19 wk
Roxadustat (n 5 33) Epoetin alfa (n 5 9) Roxadustat (n 5 61) Epoetin alfa (n 5 22)
Ferritin, ng/mL
Baseline 917.36 458.0 929.7 6 494.2 826.86 484.5 1,106.66 642.1
End of treatment 731.86 375.8 783.2 6 484.2 637.36 426.2 895.06 888.7
Change from baseline 2185.56 190.5 2146.56 180.7 2201.16 334.4 2211.66 445.2
P a 0.5 — 0.8 —
TSAT, %
Baseline 30.1 6 8.2 31.5 6 11.5 29.2 6 10.2 28.6 6 14.6
End of treatment 27.56 14.7 24.46 8.4 27.1 6 16.3 23.36 9.6
Change from baseline 22.56 13.7 27.06 4.1 22.4 6 18.9 25.3 6 12.5
P a 0.4 — 0.4 —
Serum iron, mg/dL
Baseline 70.46 20.9 70.2 6 27.2 66.4 6 20.6 63.3 6 32.0
End of treatment 77.56 34.6 56.2 6 24.0 72.1 6 39.7 57.8 6 23.3
Change from baseline 7.1 6 33.9 214.0 6 11.1 5.26 42.2 25.5 6 30.2
P a 0.07 — 0.1 —
TIBC, mg/dL
Baseline 210.86 41.3 200.86 30.9 199.76 34.0 202.16 26.7
End of treatment 261.86 48.7 205.86 39.7 236.56 44.5 227.66 54.6
Change from baseline 51.06 27.4 5.06 26.4 37.6 6 41.4 25.6 6 47.3
P a ,0.001 — 0.3 —
sTfR, mg/L
Baseline 2.746 0.86 3.25 6 0.76 4.03 6 1.81 3.69 6 0.93
End of treatment 3.436 1.54 3.44 6 1.07 4.46 6 2.64 3.34 6 1.65
Change from baseline 0.696 1.54 0.20 6 0.73 0.86 6 2.69 20.336 1.52
P a 0.6 — 0.2 —
MCV, fL
Baseline 98.7 6 5.3 99.06 6.8 99.26 6.3 99.56 8.8
End of treatment 99.9 6 6.0 99.16 7.2 97.96 6.9 97.26 9.7
Change from baseline 1.26 4.0 0.1 6 3.7 21.36 4.3 22.36 5.0
P a 0.5 — 0.4 —
CHr, pg
Baseline 32.0 6 1.5 31.86 2.6 32.86 2.2 32.56 3.0
End of treatment 32.3 6 1.9 31.16 2.0 33.56 2.6 32.86 3.1
Change from baseline 0.36 1.4 20.86 1.0 0.7 6 1.3 0.2 6 1.4
P a 0.04 — 0.2 —
Hepcidin, ng/mL
No. 33 9 46 18
Baseline 236.66 159.7 279.3 6 137.6 327.16 178.8 298.76 123.1
End of treatment 197.56 155.9 272.8 6 215.9 266.76 170.9 334.36 190.5
Change from baseline 239.26 226.9 26.5 6 140.1 260.4 6 187.8 35.6 6 123.4
P b 0.3 — 0.04 —
Note: Values given as mean 6 standard deviation.
Abbreviations: CHr, reticulocyte Hb content; MCV, mean corpuscular volume; sTfR, soluble transferrin receptor; TIBC, total iron-
binding capacity; TSAT, transferrin saturation.
P values are from aanalysis of covariance model or bKruskal-Wallis test, comparing roxadustat change from baseline with epoetin
alfa change from baseline.
Roxadustat in Dialysis-Dependent CKD Anemiato enrollment who presented volume overloaded with
respiratory failure in whom dialysis was delayed,
leading to cardiac arrest. All 3 had signiﬁcant pre-
existing cardiovascular risks. None of the deaths was
considered related to roxadustat.Am J Kidney Dis. 2016;67(6):912-924DISCUSSION
This phase 2 trial is the ﬁrst roxadustat study in
patients with ESRD on stable hemodialysis therapy
whose Hb levels were maintained with epoetin alfa
and suggests that roxadustat can maintain Hb levels919
Provenzano et alfor periods up to 19 weeks. Because of prerandom-
ization IV iron use, we realize that differences in iron
metabolic values or trends could be masked following
the exclusion of IV iron for up to 19 weeks in both
groups.
The 6-week dose range portion of this conversion
study in hemodialysis patients revealed a dose-
dependent Hb level response to roxadustat. The Hb
effect of a 1.0-mg/kg dose of roxadustat was com-
parable to, while doses $ 1.5 mg/kg were more
effective than epoetin alfa, with a pooled Hb level
response at 6 weeks of 79% versus 33%, respectively.
In subsequent clinical development, starting doses $
1.5 mg/kg will need to take into account initial Hb
level response during the period of ﬁxed dose and the
number of dose adjustments required after 4 weeks.
The roxadustat dose for Hb level maintenance ranged
from 0.5 to 3.4 (mean dose, w1.7) mg/kg thrice
weekly. The effect of roxadustat on Hb level main-
tenance was durable over the 19-week treatment
period of this study. The overall least-squares-mean
DHb during study weeks 16 to 19 of roxadustat-
treated patients was comparable to that in the epoe-
tin alfa arm. Based on these results and historical ESA
phase 3 studies,22 roxadustat appears to be effective
and comparable to epoetin alfa in maintaining Hb
levels in patients with ESRD receiving hemodialysis.
In individuals with higher baseline epoetin alfa dose
requirements (eg, cohort A-5), a somewhat higher
roxadustat dose requirement was noted, whereas the
range of roxadustat dose requirements was not as
large as observed for epoetin alfa. A longer study is
needed to determine the durability of response in such
patients and titration/dose needs.
An important difference between roxadustat and
epoetin alfa is the relationship of dose to the inﬂam-
matory parameter CRP. Inﬂammation increases an
ESRD patient’s dose requirements for epoetin alfa,
whether during correction or maintenance.21 Resis-
tance to ESAs appears to be mediated in part by
elevated hepcidin levels,10,12 which are increased in
inﬂammation, limiting iron availability. Hepcidin
impairs both iron absorption from the duodenal
enterocyte and iron release from macrophages, where
most iron is stored. This impairment of iron meta-
bolism explains why IV iron produces very high
ferritin levels, reﬂecting preferential accumulation in
macrophages. Egress is impaired because hepcidin
inactivates ferroportin, the sole iron-exporting process
in mammalian cells. This impairment in iron export is
an important mechanism leading to the increase in
epoetin alfa requirements during inﬂammation, in
effect producing functional iron deﬁciency and ac-
counting for the linear correlation of epoetin alfa
doses with baseline serum CRP levels in the epoetin
alfa group. By contrast, roxadustat maintenance dose920requirements were independent of baseline CRP
levels. This independence of response from CRP
levels suggests the potential for roxadustat to over-
come the therapeutic barrier to erythropoiesis from
the inﬂammatory component present in ESRD.
Furthermore, Hb levels in the epoetin alfa group
appeared to decline gradually over time when IV iron
supplementation was discontinued despite the in-
crease in epoetin alfa doses to maintain Hb levels.23-25
The IV iron exclusion permitted assessment of the
impact of roxadustat compared to epoetin on hepcidin
and iron delivery indexes to the erythron (reticulocyte
Hb content, mean corpuscular volume, total iron-
binding capacity, and soluble transferrin receptor) in
the coordination of erythropoiesis despite marked
differences in the relative elevations in plasma EPO
levels induced. Despite high mean ferritin levels .
800 ng/mL, larger declines in transferrin saturation,
reticulocyte Hb content, and serum iron levels
occurred in the epoetin alfa–treated than roxadustat-
treated participants. This is consistent with roxadu-
stat’s expected positive impact on iron availability.
In a subset of 6 participants, plasma EPO levels
following an oral dose of roxadustat were compared
with those following an IV dose of epoetin alfa prior
to randomization. Following IV epoetin alfa, average
plasma EPO levels increased more than 30-fold
compared with those seen in healthy persons at sea
level.26 These supraphysiologic levels after exoge-
nous epoetin alfa administration occurred even at
doses equivalent to the lowest epoetin alfa dose
quartile of hemodialysis patients.27,28 In contrast,
within the same participant, roxadustat treatment
provided modest transient postdose endogenous EPO
levels, which peaked at about one-sixth of the level
observed with exogenous epoetin alfa dosing. The
levels observed are similar to those reported in a
previous pharmacokinetics trial.19 Moreover, these
lower baseline endogenous EPO levels were effective
in maintaining Hb levels during the study and are
consistent with the physiologic EPO response in
persons under hypoxic conditions29 or following an
acute decrease in Hb level.30,31 The postdose plasma
EPO levels measured in the active comparator
(epoetin alfa) arm may be unique to this speciﬁc agent
and IV route of administration, and different routes of
administration such as subcutaneous or different
agents such as continuous erythropoietin receptor
activator (CERA) or darbepoetin alfa may result in
different pharmacokinetic proﬁles in this setting.
Roxadustat as compared to epoetin alfa treatment
resulted in different plasma EPO levels, with rox-
adustat exposing patients to modest levels of endog-
enous EPO within or near physiologic range. In
contrast, the peak and area under the curve of plasma
EPO concentrations at the mean of the lowest doseAm J Kidney Dis. 2016;67(6):912-924
Table 5. SAEs by Treatment Group
Roxadustat (n 5 108) Epoetin alfa (n 5 36)
No. with $1 SAE 26 (24.1) 6 (17)
System organ class and preferred term
Infections and infestations 8 (7.4) 3 (8)
Gastroenteritis 2 (1.9) 0 (0)
Cellulitis 1 (0.9) 0 (0)
Diabetic gangrene 1 (0.9) 0 (0)
Endocarditis bacterial 1 (0.9) 0 (0)
Pneumonia 1 (0.9) 1 (3)
Sepsis 1 (0.9) 0 (0)
Gangrene 1 (0.9) 1 (3)
Infection 0 (0) 1 (3)
Metabolism and nutrition disorders 5 (4.6) 4 (11)
Fluid overload 2 (1.9) 1 (3)
Hyperkalemia 1 (0.9) 2 (6)
Diabetic ketoacidosis 1 (0.9) 0 (0)
Hypocalcemia 1 (0.9) 0 (0)
Hypokalemia 1 (0.9) 0 (0)
Diabetes mellitus inadequate control 0 (0) 1 (3)
Hyperglycemia 0 (0) 1 (3)
Cardiac disorders 4 (3.7) 2 (6)
Acute myocardial infarction 2 (1.9) 0 (0)
Cardiac failure congestive 1 (0.9) 1 (3)
Cardiorespiratory arrest 1 (0.9) 0 (0)
Cardiac arrest 0 (0) 1 (3)
Coronary artery disease 0 (0) 1 (3)
Myocardial infarction 0 (0) 1 (3)
Gastrointestinal disorders 3 (2.8) 0 (0)
Gastrointestinal hemorrhage 1 (0.9) 0 (0)
Pancreatitis acutea 1 (0.9) 0 (0)
Nausea 1 (0.9) 0 (0)
Vomiting 1 (0.9) 0 (0)
Injury, poisoning and procedural complications 2 (1.9) 0 (0)
Arteriovenous fistula site hemorrhage 1 (0.9) 0 (0)
Vascular graft complication 1 (0.9) 0 (0)
Nervous system disorders 2 (1.9) 0 (0)
Cerebrovascular accident 2 (1.9) 0 (0)
Complex partial seizures 1 (0.9) 0 (0)
Respiratory, thoracic, and mediastinal disorders 2 (1.9) 1 (3)
Chronic obstructive pulmonary disease 1 (0.9) 0 (0)
Pulmonary edema 1 (0.9) 0 (0)
Dyspnea 0 (0) 1 (3)
General disorders and administration site conditions 1 (0.9) 0 (0)
Sudden cardiac death 1 (0.9) 0 (0)
Immune system disorders 1 (0.9) 0 (0)
Hypersensitivity 1 (0.9) 0 (0)
Musculoskeletal and connective tissue disorders 1 (0.9) 0 (0)
Musculoskeletal chest pain 1 (0.9) 0 (0)
Neoplasms benign, malignant, and unspecifiedb 1 (0.9) 0 (0)
Thyroid neoplasm 1 (0.9) 0 (0)
Psychiatric disorders 1 (0.9) 0 (0)
Major depression 1 (0.9) 0 (0)
Skin and subcutaneous tissue disorders 1 (0.9) 0 (0)
Subcutaneous emphysema 1 (0.9) 0 (0)
(Continued)
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Table 5 (Cont’d). SAEs by Treatment Group
Roxadustat (n 5 108) Epoetin alfa (n 5 36)
Blood and lymphatic system disorders 0 (0) 1 (3)
Anemia 0 (0) 1 (3)
Vascular disorders 0 (0) 1 (3)
Peripheral vascular disorder 0 (0) 1 (3)
Note: Values given as number (percentage). For system organ class incidence, SAEs of the same system organ class in the same
patient are counted once only.
Abbreviation: SAE, serious adverse event.
aSAE of acute pancreatitis. This SAE occurred in a 40-year-old man with diabetes mellitus, hyperparathyroidism, hypertension,
dyslipidemia, kidney stones, gallstones, and status post cholecystectomy who was a smoker (10 years) and also taking lisinopril and
hydrocodone bitartrate plus acetaminophen concomitantly. He presented with a 1-week history of abdominal pain 2 days after his last
dose of a 43-day course of roxadustat and acute pancreatitis was diagnosed. Lisinopril and hydrocodone bitartrate plus acetamino-
phen were stopped, and the patient was hospitalized. The episode of pancreatitis resolved in 8 days. Another episode of pancreatitis in
this patient was reported 28 months after the last dose of study medication. Although the investigator considered the SAE of acute
pancreatitis as possibly related to roxadustat, both the sponsor and the independent data monitoring committee considered it unrelated
because of lack of temporal relationship, potential alternative causes, and the recurrence of pancreatitis when off roxadustat therapy
for 28 months. All other SAEs were considered by investigators and sponsor to be unrelated to study medication.
bIncluding cysts and polyps.
Provenzano et alquartile of exogenous epoetin alfa led to much higher
levels of exposure.28 Although ESA dose has been
implicated as part of the pathway leading to excessive
mortality and cardiovascular events when targeting
higher Hb levels, particularly in patients with in-
ﬂammation and hyporesponsive patients,8,32 it has not
been proved if this is mediated through higher EPO
levels. The potential of roxadustat as a novel thera-
peutic agent alternative to ESAs to safely treat to a
higher Hb level without the need for supraphysiologic
epoetin alfa doses might be suggested by 2 observa-
tions. First, patients who achieve higher Hb levels at
lower ESA doses have lower morbidity and better
survival.33 Second, when Hb levels are . 12.5 g/dL,
with a mean Hb level of 13.5 g/dL, and are sponta-
neously maintained by endogenous EPO production,
no increased risk was shown in more than 600 dial-
ysis patients.34 Although this potential cannot be
evaluated within the context of this phase 2 trial, it
will be further explored in phase 3.
Another important difference is the effect of rox-
adustat on serum cholesterol levels. The potential
cholesterol-lowering effect of roxadustat was inde-
pendent of statin use and may be mediated in part by
the effects of HIF on degradation 3-hydroxy-3-
methylglutaryl coenzyme A reductase, a rate-
limiting enzyme in cholesterol biosynthesis.35
Cholesterol reduction has been reported during high
altitude exposure itself.36
Observations from the current study suggest no
obvious safety concerns because the AEs and SAEs
reported are consistent with the dialysis patient pop-
ulation. The exploratory composite safety event rate
in the 19-week participants was numerically lower in
roxadustat-treated compared with epoetin alfa–treated
participants.922Limitations of this phase 2 study include its rela-
tively short treatment duration and small sample size.
As is true for all phase 2 programs, these limitations
may have precluded the identiﬁcation of a greater risk
for uncommon events.37 A much larger sample size
with longer treatment duration would be needed to
provide adequate power for manifestation of such
toxicities and comparison of cardiovascular safety
between roxadustat and ESAs.
In summary, roxadustat, an oral HIF-PHI, was
shown to maintain Hb levels in maintenance hemo-
dialysis patients with ESRD receiving a wide range of
epoetin alfa doses without IV iron in the short term.
Roxadustat also reduced hepcidin levels and regulated
iron metabolism. Further development in adequate
and well-controlled phase 3 studies is in progress
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